Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997066 | 1.00 | PIK3CD (0.39) | PIK3CDTLR7DRD4PDE4D | |
| SCHEMBL20249095 | 0.88 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL105008 | 0.86 | PIK3CD (0.47) | PIK3CDPDE4D | |
| SCHEMBL16922221 | 0.81 | — | — | |
| SCHEMBL18427458 | 0.79 | — | — | |
| SCHEMBL16272959 | 0.77 | — | — | |
| SCHEMBL12657110 | 0.77 | — | — | |
| SCHEMBL170705 | 0.77 | — | — | |
| SCHEMBL25091045 | 0.76 | OPRM1 (0.34) | TLR7DRD4 | |
| SCHEMBL12039807 | 0.75 | PIK3CD (0.38) | PIK3CDTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-8329735-B2 | Tetrazole compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120071529-A1 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071529-A1 | Tetrazole Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PIK3CD 2382/4885TLR7 287/4885DRD4 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.